Jeffrey S. Hatfield

Director, Ambit Biosciences.

Companies

VIR BiotechnologyBoard member Dec 11, 2020 to now¹
Viridian Therapeutics, Inc.\DEBoard member Aug 11, 2017 to Feb 8, 2021²
aTyr PharmaBoard member Apr 4, 2017 to May 8, 2020³
Zafgen (United States)Board member Oct 11, 2017 to Jan 24, 2019⁴
Zafgen (United States)Chief executive officer Oct 11, 2017 to Jan 24, 2019⁴
INVIVO THERAPEUTICS HOLDINGS CORP.Board member Nov 3, 2016 to Jan 23, 2018⁵
Ambit BiosciencesBoard member Jun 4, 2014 to Nov 12, 2014⁶

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

VIR Biotechnology VIR39,806 shares⁷$407.4K at $10.23May 27, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

May 27, 2026Granted 8,000 shares of VIR Biotechnology⁷
May 30, 2025Granted 8,000 shares of VIR Biotechnology⁸
May 30, 2024Granted 8,000 shares of VIR Biotechnology⁹
May 22, 2023Granted 6,027 shares of VIR Biotechnology¹⁰
May 23, 2022Granted 6,405 shares of VIR Biotechnology¹¹

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARVIR Biotechnology, Board member
2
SEC EDGARViridian Therapeutics, Inc.\DE, Board member
3
SEC EDGARaTyr Pharma, Board member
4
SEC EDGARZafgen (United States), Board member
5
SEC EDGARINVIVO THERAPEUTICS HOLDINGS CORP., Board member
6
SEC EDGARAmbit Biosciences, Board member
7
SEC EDGARVIR Biotechnology shares after the filing of May 27, 2026
8
SEC EDGARForm 4 filed Jun 2, 2025
9
SEC EDGARForm 4 filed Jun 3, 2024
10
SEC EDGARForm 4 filed May 24, 2023
11
SEC EDGARForm 4 filed May 25, 2022